M. John Chapman BSc, PhD, DSc, FESC, is Research Professor at the University of Pierre and Marie Curie, and Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière University Hospital in Paris, France. He is President of the European Atherosclerosis Society to 2013; in this role, he has actively supported the development of new Joint Guidelines for the Management of Dyslipidemia with the European Society of Cardiology, and together with Prof Henry Ginsberg, has spearheaded the recent EAS Consensus Panel initiatives focussed on Lipoprotein Lp(a) and on atherogenic high triglyceride / low HDL dyslipidemia as major cardiovascular risk factors.
Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, at the Gladstone Foundation for Cardiovascular Disease in the same city, at the Biophysics Institute , Boston University, and at Southwestern Medical School in Dallas. Professor Chapman is a Past-President of the French Atherosclerosis Society, past Co-Chairman of the International HDL Awards Committee, and a Founder Member of the European Lipoprotein Conference.
John Chapman is Associate European Editor of "Arteriosclerosis, Thrombosis and Vascular Biology" and of "Pharmacology and Therapeutics". He is Editorial Board member of the "Journal of Lipid Research", "Atherosclerosis", " Future Lipidology", "Vascular Pharmacology" and "Clinical lipidology" and has authored numerous publications and book chapters, including articles in Nature, Nature Structural and Molecular Biology, Nature Cardiovascular Medicine, Pharmacological Reviews, PNAS, Circulation, Circulation Research, J Cell Biol, Eur Heart J, FASEB J. and New Engl J Med. He serves on several international advisory boards and on Steering Committees of clinical intervention trials, including the recent SATURN trial. John Chapman has presented plenary conferences worldwide.
In recognition of his original career contributions to the field of "Plasma lipoproteins : Structure, Metabolism and Role in Atherothrombosis", he was awarded the Doctor of Science degree by the University of London in 2002. The focal points of his research interests have been (i) the structure, metabolism, and biological activities of atherogenic apo.B-containing particle subspecies (VLDL, LDL and Lp(a)), (ii) the relationship of the lipidome and proteome of HDL particle subspecies to atheroprotective activity in normolipidemia and in atherogenic dyslipidemia, (iii) the role of CETP in the regulation of intravascular lipoprotein metabolism, (iv) the pharmacological modulation of lipoprotein metabolism in atherogenic dyslipidemias and metabolic disease, (v) the role of monocyte-macrophages and foam cells in the inflammatory destabilisation and thrombogenicity of the atherosclerotic plaque, and (vi) the comparative aspects of lipid transport and metabolism in animal species.
In 2009, he received a Distinguished Career Award from the International Atherosclerosis Society for his contributions to the field. In 2011, John chaired the Gordon Research Conference on Atherosclerosis in Newport , RI, USA, and was Vice-Chair of the same conference in 2009. In 2010 and 2011, Professor Chapman was awarded a Prize for Scientific Excellence by INSERM.
In 2012, an authoritative treatise on High Density Lipoproteins, entitled "HDL : Structure, Metabolism, Function and Therapeutics" and co-authored by Dr Anatol Kontush and Prof Chapman, was published by Wiley.